| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ketamine | 60 | 2025 | 215 | 16.200 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 45 | 2025 | 116 | 12.840 |
Why?
|
| Depressive Disorder, Major | 54 | 2025 | 401 | 11.320 |
Why?
|
| Antidepressive Agents | 51 | 2025 | 290 | 9.340 |
Why?
|
| Excitatory Amino Acid Antagonists | 17 | 2023 | 95 | 3.490 |
Why?
|
| Anxiety Disorders | 24 | 2020 | 685 | 3.450 |
Why?
|
| Electroconvulsive Therapy | 9 | 2025 | 68 | 3.400 |
Why?
|
| Depression | 28 | 2024 | 1248 | 3.330 |
Why?
|
| Riluzole | 9 | 2019 | 21 | 2.630 |
Why?
|
| Anti-Anxiety Agents | 10 | 2019 | 73 | 2.320 |
Why?
|
| Aspartic Acid | 9 | 2015 | 74 | 1.900 |
Why?
|
| Suicide | 6 | 2023 | 177 | 1.760 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 7 | 2022 | 149 | 1.650 |
Why?
|
| Prefrontal Cortex | 8 | 2024 | 178 | 1.650 |
Why?
|
| Double-Blind Method | 31 | 2025 | 1619 | 1.500 |
Why?
|
| Antipsychotic Agents | 5 | 2023 | 373 | 1.450 |
Why?
|
| Stress Disorders, Post-Traumatic | 12 | 2021 | 630 | 1.420 |
Why?
|
| Hippocampus | 12 | 2017 | 830 | 1.360 |
Why?
|
| Mood Disorders | 11 | 2023 | 127 | 1.350 |
Why?
|
| Adult | 81 | 2025 | 29397 | 1.290 |
Why?
|
| Humans | 149 | 2025 | 124404 | 1.250 |
Why?
|
| Magnetic Resonance Spectroscopy | 10 | 2017 | 290 | 1.240 |
Why?
|
| Treatment Outcome | 53 | 2025 | 12287 | 1.210 |
Why?
|
| Anxiety | 10 | 2023 | 966 | 1.200 |
Why?
|
| Anhedonia | 8 | 2023 | 31 | 1.090 |
Why?
|
| Psychiatric Status Rating Scales | 21 | 2024 | 811 | 1.030 |
Why?
|
| Infusions, Intravenous | 14 | 2022 | 548 | 1.000 |
Why?
|
| Cerebral Cortex | 4 | 2023 | 455 | 0.990 |
Why?
|
| Middle Aged | 60 | 2025 | 26460 | 0.910 |
Why?
|
| Reward | 5 | 2024 | 110 | 0.900 |
Why?
|
| Connectome | 2 | 2024 | 99 | 0.870 |
Why?
|
| Lorazepam | 1 | 2023 | 12 | 0.860 |
Why?
|
| Suicidal Ideation | 10 | 2023 | 219 | 0.830 |
Why?
|
| Glutamic Acid | 8 | 2017 | 201 | 0.820 |
Why?
|
| Fatigue Syndrome, Chronic | 3 | 2012 | 9 | 0.800 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 6 | 2019 | 20 | 0.800 |
Why?
|
| Female | 82 | 2025 | 66305 | 0.790 |
Why?
|
| Deep Brain Stimulation | 8 | 2024 | 410 | 0.780 |
Why?
|
| Cerebral Ventricles | 3 | 2012 | 82 | 0.770 |
Why?
|
| Male | 74 | 2025 | 61028 | 0.760 |
Why?
|
| Lactic Acid | 3 | 2012 | 147 | 0.760 |
Why?
|
| Bipolar Disorder | 6 | 2022 | 351 | 0.730 |
Why?
|
| Azabicyclo Compounds | 5 | 2019 | 16 | 0.720 |
Why?
|
| Analgesics | 2 | 2014 | 135 | 0.720 |
Why?
|
| Oxadiazoles | 5 | 2019 | 25 | 0.720 |
Why?
|
| Choline | 5 | 2015 | 54 | 0.720 |
Why?
|
| Creatine | 6 | 2015 | 41 | 0.720 |
Why?
|
| Habenula | 1 | 2021 | 45 | 0.700 |
Why?
|
| Midazolam | 9 | 2022 | 49 | 0.690 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 256 | 0.690 |
Why?
|
| Stress, Psychological | 10 | 2015 | 560 | 0.680 |
Why?
|
| Drugs, Investigational | 1 | 2019 | 22 | 0.660 |
Why?
|
| Suicide, Attempted | 2 | 2020 | 133 | 0.650 |
Why?
|
| Cognition | 8 | 2019 | 737 | 0.640 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2023 | 1099 | 0.610 |
Why?
|
| Gyrus Cinguli | 7 | 2024 | 113 | 0.600 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2018 | 115 | 0.590 |
Why?
|
| Alcoholism | 1 | 2020 | 231 | 0.570 |
Why?
|
| Intelligence | 1 | 2017 | 98 | 0.560 |
Why?
|
| Young Adult | 24 | 2024 | 8979 | 0.560 |
Why?
|
| Drug Resistance | 5 | 2015 | 256 | 0.540 |
Why?
|
| Adult Survivors of Child Abuse | 2 | 2017 | 13 | 0.540 |
Why?
|
| Folic Acid Deficiency | 1 | 2017 | 53 | 0.540 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2024 | 3578 | 0.520 |
Why?
|
| Aripiprazole | 3 | 2024 | 20 | 0.510 |
Why?
|
| Depressive Disorder | 5 | 2021 | 456 | 0.510 |
Why?
|
| Parietal Lobe | 1 | 2015 | 42 | 0.500 |
Why?
|
| Brain Chemistry | 2 | 2008 | 124 | 0.500 |
Why?
|
| Clozapine | 1 | 2015 | 24 | 0.500 |
Why?
|
| Emotions | 2 | 2015 | 365 | 0.480 |
Why?
|
| gamma-Aminobutyric Acid | 5 | 2015 | 174 | 0.480 |
Why?
|
| Narcotic Antagonists | 3 | 2020 | 107 | 0.470 |
Why?
|
| Brain | 9 | 2023 | 3003 | 0.470 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 138 | 0.460 |
Why?
|
| Corticotropin-Releasing Hormone | 7 | 2011 | 58 | 0.460 |
Why?
|
| Glutathione | 2 | 2014 | 194 | 0.450 |
Why?
|
| Glycine Plasma Membrane Transport Proteins | 1 | 2013 | 4 | 0.450 |
Why?
|
| Sarcosine | 1 | 2013 | 10 | 0.440 |
Why?
|
| Impulsive Behavior | 3 | 2020 | 145 | 0.420 |
Why?
|
| Anesthetics, Dissociative | 1 | 2013 | 20 | 0.420 |
Why?
|
| Triazines | 2 | 2012 | 29 | 0.420 |
Why?
|
| Electroencephalography | 5 | 2024 | 868 | 0.410 |
Why?
|
| Piperazines | 3 | 2008 | 233 | 0.400 |
Why?
|
| Overweight | 2 | 2020 | 360 | 0.390 |
Why?
|
| Drug Therapy, Combination | 6 | 2023 | 1154 | 0.390 |
Why?
|
| Antimanic Agents | 2 | 2012 | 37 | 0.390 |
Why?
|
| Bayes Theorem | 3 | 2021 | 282 | 0.380 |
Why?
|
| Neurokinin-1 Receptor Antagonists | 1 | 2010 | 5 | 0.370 |
Why?
|
| Neurotransmitter Agents | 2 | 2008 | 144 | 0.360 |
Why?
|
| Transcranial Magnetic Stimulation | 3 | 2024 | 71 | 0.350 |
Why?
|
| Tetrazoles | 1 | 2010 | 63 | 0.350 |
Why?
|
| Oxidative Stress | 2 | 2014 | 813 | 0.340 |
Why?
|
| Maternal Behavior | 4 | 2010 | 66 | 0.340 |
Why?
|
| Animals | 25 | 2023 | 34145 | 0.340 |
Why?
|
| Glutamine | 2 | 2008 | 210 | 0.330 |
Why?
|
| Treatment Failure | 3 | 2017 | 342 | 0.330 |
Why?
|
| Case-Control Studies | 8 | 2017 | 3268 | 0.330 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 5 | 2017 | 28 | 0.330 |
Why?
|
| Functional Laterality | 6 | 2017 | 182 | 0.330 |
Why?
|
| Sulfonamides | 2 | 2008 | 261 | 0.330 |
Why?
|
| Fear | 7 | 2019 | 201 | 0.330 |
Why?
|
| Administration, Intravenous | 4 | 2023 | 143 | 0.330 |
Why?
|
| Phenethylamines | 2 | 2021 | 14 | 0.330 |
Why?
|
| Occipital Lobe | 5 | 2014 | 32 | 0.320 |
Why?
|
| Time Factors | 12 | 2020 | 6273 | 0.320 |
Why?
|
| Piperidines | 1 | 2010 | 204 | 0.320 |
Why?
|
| Receptors, AMPA | 2 | 2007 | 49 | 0.320 |
Why?
|
| Publication Bias | 1 | 2009 | 13 | 0.320 |
Why?
|
| Aged | 19 | 2025 | 19479 | 0.310 |
Why?
|
| Adolescent | 19 | 2024 | 19358 | 0.310 |
Why?
|
| Pilot Projects | 7 | 2020 | 1404 | 0.310 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2008 | 23 | 0.310 |
Why?
|
| Psychometrics | 3 | 2023 | 678 | 0.310 |
Why?
|
| Research Design | 4 | 2019 | 687 | 0.300 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2007 | 6 | 0.290 |
Why?
|
| Anticonvulsants | 2 | 2008 | 380 | 0.290 |
Why?
|
| National Institute of Mental Health (U.S.) | 2 | 2018 | 13 | 0.290 |
Why?
|
| Pyridines | 2 | 2021 | 229 | 0.290 |
Why?
|
| Neuroprotective Agents | 2 | 2020 | 157 | 0.280 |
Why?
|
| Clinical Trials as Topic | 5 | 2019 | 1086 | 0.280 |
Why?
|
| Brain Injuries | 1 | 2013 | 764 | 0.270 |
Why?
|
| Precision Medicine | 2 | 2023 | 315 | 0.270 |
Why?
|
| Macaca radiata | 9 | 2015 | 15 | 0.260 |
Why?
|
| Meta-Analysis as Topic | 2 | 2022 | 155 | 0.260 |
Why?
|
| Cross-Over Studies | 3 | 2023 | 312 | 0.260 |
Why?
|
| Self Report | 6 | 2023 | 522 | 0.260 |
Why?
|
| Hydrocortisone | 2 | 2004 | 219 | 0.260 |
Why?
|
| Biomarkers | 6 | 2023 | 2980 | 0.260 |
Why?
|
| Disability Evaluation | 2 | 2019 | 193 | 0.260 |
Why?
|
| Drug Administration Schedule | 5 | 2019 | 725 | 0.250 |
Why?
|
| Phobic Disorders | 1 | 2006 | 42 | 0.250 |
Why?
|
| Personality Inventory | 3 | 2013 | 167 | 0.250 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 1088 | 0.240 |
Why?
|
| Psychiatry | 2 | 2021 | 263 | 0.240 |
Why?
|
| Analgesics, Opioid | 2 | 2020 | 409 | 0.240 |
Why?
|
| Combined Modality Therapy | 5 | 2024 | 1245 | 0.240 |
Why?
|
| Venlafaxine Hydrochloride | 1 | 2024 | 10 | 0.230 |
Why?
|
| Serotonin | 4 | 2009 | 232 | 0.220 |
Why?
|
| Stereotaxic Techniques | 1 | 2024 | 70 | 0.220 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2024 | 112 | 0.220 |
Why?
|
| Affect | 1 | 2024 | 159 | 0.220 |
Why?
|
| Random Allocation | 2 | 2021 | 436 | 0.220 |
Why?
|
| Patient Preference | 1 | 2025 | 119 | 0.220 |
Why?
|
| Area Under Curve | 2 | 2023 | 315 | 0.220 |
Why?
|
| Organ Size | 4 | 2015 | 432 | 0.210 |
Why?
|
| Quetiapine Fumarate | 1 | 2023 | 16 | 0.210 |
Why?
|
| DNA Methylation | 2 | 2021 | 1003 | 0.210 |
Why?
|
| Mental Disorders | 2 | 2024 | 824 | 0.210 |
Why?
|
| Delayed-Action Preparations | 1 | 2023 | 111 | 0.210 |
Why?
|
| Self Concept | 1 | 2024 | 161 | 0.210 |
Why?
|
| Sexual Maturation | 1 | 2002 | 48 | 0.200 |
Why?
|
| Outpatients | 1 | 2023 | 253 | 0.190 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2022 | 32 | 0.190 |
Why?
|
| Hospitals, Psychiatric | 1 | 2022 | 68 | 0.190 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 87 | 0.190 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 511 | 0.190 |
Why?
|
| Membrane Transport Modulators | 1 | 2021 | 5 | 0.190 |
Why?
|
| KCNQ3 Potassium Channel | 1 | 2021 | 19 | 0.180 |
Why?
|
| Phenylenediamines | 1 | 2021 | 25 | 0.180 |
Why?
|
| Ventral Striatum | 1 | 2021 | 33 | 0.180 |
Why?
|
| United States | 8 | 2024 | 10773 | 0.180 |
Why?
|
| Carbamates | 1 | 2021 | 60 | 0.180 |
Why?
|
| KCNQ2 Potassium Channel | 1 | 2021 | 41 | 0.180 |
Why?
|
| Linear Models | 3 | 2017 | 671 | 0.180 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2020 | 22 | 0.170 |
Why?
|
| Pyrrolidines | 1 | 2020 | 36 | 0.170 |
Why?
|
| Pain | 2 | 2015 | 472 | 0.170 |
Why?
|
| Demography | 2 | 2012 | 240 | 0.170 |
Why?
|
| Benzamides | 1 | 2020 | 106 | 0.160 |
Why?
|
| Placebos | 2 | 2010 | 241 | 0.160 |
Why?
|
| Brain Mapping | 4 | 2023 | 398 | 0.160 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 605 | 0.160 |
Why?
|
| Ambulatory Care | 2 | 2017 | 380 | 0.160 |
Why?
|
| Epilepsy | 2 | 2024 | 872 | 0.160 |
Why?
|
| Injections, Intravenous | 2 | 2010 | 254 | 0.160 |
Why?
|
| Reflex, Startle | 1 | 2019 | 32 | 0.160 |
Why?
|
| Wearable Electronic Devices | 1 | 2021 | 101 | 0.160 |
Why?
|
| Mindfulness | 1 | 2019 | 20 | 0.160 |
Why?
|
| Equivalence Trials as Topic | 1 | 2018 | 12 | 0.160 |
Why?
|
| Feasibility Studies | 1 | 2022 | 767 | 0.160 |
Why?
|
| Premenopause | 1 | 2019 | 30 | 0.160 |
Why?
|
| Pharmacogenomic Testing | 1 | 2018 | 37 | 0.160 |
Why?
|
| Conditioning, Classical | 1 | 2019 | 53 | 0.160 |
Why?
|
| Epigenesis, Genetic | 2 | 2021 | 675 | 0.160 |
Why?
|
| Receptors, Metabotropic Glutamate | 2 | 2010 | 45 | 0.160 |
Why?
|
| Serotonin 5-HT1 Receptor Agonists | 2 | 2008 | 3 | 0.150 |
Why?
|
| Psychotherapy | 2 | 2019 | 231 | 0.150 |
Why?
|
| Serum | 1 | 2018 | 47 | 0.150 |
Why?
|
| Postmenopause | 1 | 2019 | 123 | 0.150 |
Why?
|
| Plasma | 1 | 2018 | 96 | 0.150 |
Why?
|
| Algorithms | 1 | 2024 | 1612 | 0.140 |
Why?
|
| Databases, Factual | 2 | 2013 | 1174 | 0.140 |
Why?
|
| Drug Design | 2 | 2017 | 146 | 0.140 |
Why?
|
| Off-Label Use | 1 | 2017 | 27 | 0.140 |
Why?
|
| Cocaine-Related Disorders | 1 | 2019 | 202 | 0.140 |
Why?
|
| Hypothalamo-Hypophyseal System | 4 | 2014 | 63 | 0.140 |
Why?
|
| Nucleus Accumbens | 1 | 2017 | 54 | 0.140 |
Why?
|
| Sex Characteristics | 1 | 2019 | 318 | 0.140 |
Why?
|
| Synaptic Transmission | 2 | 2012 | 351 | 0.130 |
Why?
|
| Sleep Wake Disorders | 1 | 2019 | 179 | 0.130 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2016 | 52 | 0.130 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 3 | 2008 | 211 | 0.130 |
Why?
|
| Central Nervous System Agents | 2 | 2020 | 15 | 0.130 |
Why?
|
| Retrospective Studies | 4 | 2022 | 16233 | 0.130 |
Why?
|
| Psychotropic Drugs | 1 | 2017 | 124 | 0.130 |
Why?
|
| Antisocial Personality Disorder | 1 | 2016 | 63 | 0.130 |
Why?
|
| Follow-Up Studies | 3 | 2013 | 5107 | 0.130 |
Why?
|
| Severity of Illness Index | 3 | 2024 | 2896 | 0.130 |
Why?
|
| Lithium Compounds | 1 | 2015 | 14 | 0.130 |
Why?
|
| Isoquinolines | 1 | 2015 | 40 | 0.120 |
Why?
|
| Neuropsychological Tests | 5 | 2019 | 929 | 0.120 |
Why?
|
| Neuronal Plasticity | 3 | 2023 | 273 | 0.120 |
Why?
|
| Pituitary-Adrenal System | 3 | 2014 | 36 | 0.120 |
Why?
|
| Surveys and Questionnaires | 4 | 2015 | 3734 | 0.120 |
Why?
|
| Body Mass Index | 2 | 2020 | 1550 | 0.120 |
Why?
|
| Testosterone | 1 | 2020 | 534 | 0.120 |
Why?
|
| Benzodiazepines | 2 | 2022 | 101 | 0.120 |
Why?
|
| Olfactory Cortex | 1 | 2015 | 3 | 0.120 |
Why?
|
| Attention | 1 | 2016 | 197 | 0.120 |
Why?
|
| Pyridazines | 1 | 2015 | 51 | 0.120 |
Why?
|
| Corpus Callosum | 2 | 2015 | 98 | 0.120 |
Why?
|
| Hallucinations | 1 | 2015 | 26 | 0.120 |
Why?
|
| Internationality | 1 | 2015 | 131 | 0.120 |
Why?
|
| Internal Capsule | 2 | 2015 | 51 | 0.120 |
Why?
|
| Immune System Diseases | 1 | 2015 | 46 | 0.120 |
Why?
|
| Parkinson Disease | 1 | 2021 | 693 | 0.120 |
Why?
|
| Affective Symptoms | 1 | 2015 | 60 | 0.120 |
Why?
|
| Hormone Antagonists | 1 | 2014 | 60 | 0.110 |
Why?
|
| Comparative Effectiveness Research | 2 | 2025 | 68 | 0.110 |
Why?
|
| Substance-Related Disorders | 1 | 2019 | 459 | 0.110 |
Why?
|
| Diffusion Tensor Imaging | 4 | 2023 | 238 | 0.110 |
Why?
|
| Electrodes, Implanted | 2 | 2024 | 168 | 0.110 |
Why?
|
| White Matter | 1 | 2015 | 180 | 0.110 |
Why?
|
| Child | 5 | 2021 | 24526 | 0.110 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 3 | 2011 | 44 | 0.100 |
Why?
|
| Drug Administration Routes | 1 | 2012 | 32 | 0.100 |
Why?
|
| Feeding Behavior | 3 | 2010 | 713 | 0.100 |
Why?
|
| Memantine | 1 | 2012 | 17 | 0.100 |
Why?
|
| Dopamine Agents | 1 | 2012 | 28 | 0.100 |
Why?
|
| Spin Labels | 1 | 2012 | 39 | 0.100 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 405 | 0.100 |
Why?
|
| Risk Factors | 2 | 2023 | 10149 | 0.100 |
Why?
|
| Phosphates | 1 | 2012 | 115 | 0.090 |
Why?
|
| Intracranial Hypertension | 1 | 2013 | 121 | 0.090 |
Why?
|
| Down-Regulation | 1 | 2014 | 701 | 0.090 |
Why?
|
| Regional Blood Flow | 1 | 2012 | 209 | 0.090 |
Why?
|
| Substance P | 1 | 2010 | 34 | 0.090 |
Why?
|
| Placebo Effect | 2 | 2022 | 24 | 0.090 |
Why?
|
| Tryptophan | 1 | 2011 | 90 | 0.090 |
Why?
|
| Panic Disorder | 2 | 2008 | 45 | 0.090 |
Why?
|
| Signal Transduction | 2 | 2017 | 4535 | 0.090 |
Why?
|
| Recurrence | 2 | 2019 | 1423 | 0.090 |
Why?
|
| Behavior, Animal | 4 | 2011 | 492 | 0.090 |
Why?
|
| Genotype | 3 | 2021 | 2552 | 0.090 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 628 | 0.090 |
Why?
|
| Gap Junctions | 1 | 2010 | 38 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2020 | 1688 | 0.080 |
Why?
|
| Quality of Life | 3 | 2024 | 1954 | 0.080 |
Why?
|
| Veterans | 1 | 2020 | 1752 | 0.080 |
Why?
|
| Drug Industry | 1 | 2009 | 46 | 0.080 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2009 | 32 | 0.080 |
Why?
|
| Functional Neuroimaging | 2 | 2021 | 30 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 2031 | 0.080 |
Why?
|
| Cerebrovascular Circulation | 1 | 2012 | 433 | 0.080 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2008 | 18 | 0.080 |
Why?
|
| Receptors, Glutamate | 1 | 2008 | 16 | 0.080 |
Why?
|
| United States Food and Drug Administration | 1 | 2009 | 150 | 0.080 |
Why?
|
| Bias | 1 | 2009 | 131 | 0.080 |
Why?
|
| Drug Interactions | 1 | 2009 | 253 | 0.070 |
Why?
|
| Neurobiology | 1 | 2008 | 25 | 0.070 |
Why?
|
| Hallucinogens | 1 | 2009 | 43 | 0.070 |
Why?
|
| Tetrahydrofolates | 1 | 2008 | 17 | 0.070 |
Why?
|
| Vagus Nerve | 1 | 2008 | 45 | 0.070 |
Why?
|
| Single-Blind Method | 1 | 2008 | 237 | 0.070 |
Why?
|
| Receptors, Kainic Acid | 1 | 2007 | 5 | 0.070 |
Why?
|
| Quinolones | 1 | 2008 | 53 | 0.070 |
Why?
|
| Secondary Prevention | 1 | 2009 | 214 | 0.070 |
Why?
|
| Metabolic Syndrome | 1 | 2011 | 330 | 0.070 |
Why?
|
| Neuropeptides | 1 | 2008 | 114 | 0.070 |
Why?
|
| Schizophrenia | 1 | 2010 | 301 | 0.070 |
Why?
|
| Inpatients | 2 | 2022 | 496 | 0.070 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2008 | 53 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2874 | 0.070 |
Why?
|
| Social Dominance | 2 | 2006 | 9 | 0.070 |
Why?
|
| Polymorphism, Genetic | 2 | 2009 | 810 | 0.070 |
Why?
|
| Prosencephalon | 1 | 2006 | 42 | 0.070 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2006 | 25 | 0.060 |
Why?
|
| Frontal Lobe | 1 | 2006 | 111 | 0.060 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2006 | 106 | 0.060 |
Why?
|
| Appetitive Behavior | 1 | 2005 | 14 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2017 | 3382 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2018 | 2615 | 0.060 |
Why?
|
| Beta Rhythm | 1 | 2024 | 22 | 0.060 |
Why?
|
| Duloxetine Hydrochloride | 1 | 2024 | 11 | 0.060 |
Why?
|
| Monte Carlo Method | 1 | 2024 | 96 | 0.060 |
Why?
|
| Alfaxalone Alfadolone Mixture | 1 | 2003 | 1 | 0.060 |
Why?
|
| Positron-Emission Tomography | 1 | 2006 | 298 | 0.060 |
Why?
|
| GABA Antagonists | 1 | 2003 | 20 | 0.060 |
Why?
|
| Neural Pathways | 1 | 2005 | 266 | 0.060 |
Why?
|
| Electrodes | 1 | 2023 | 99 | 0.050 |
Why?
|
| Neurophysiological Monitoring | 1 | 2024 | 37 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2006 | 384 | 0.050 |
Why?
|
| Sleep Stages | 1 | 2003 | 32 | 0.050 |
Why?
|
| Choice Behavior | 1 | 2024 | 131 | 0.050 |
Why?
|
| Anisotropy | 2 | 2015 | 122 | 0.050 |
Why?
|
| Receptors, Neurotransmitter | 1 | 2002 | 21 | 0.050 |
Why?
|
| Temporal Lobe | 1 | 2003 | 115 | 0.050 |
Why?
|
| Homovanillic Acid | 1 | 2002 | 25 | 0.050 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 2002 | 28 | 0.050 |
Why?
|
| Analysis of Variance | 3 | 2011 | 1018 | 0.050 |
Why?
|
| Circadian Rhythm | 1 | 2004 | 274 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2006 | 556 | 0.050 |
Why?
|
| Psychotic Disorders | 1 | 2023 | 136 | 0.050 |
Why?
|
| Child Abuse | 1 | 2004 | 195 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2024 | 368 | 0.050 |
Why?
|
| Kynurenic Acid | 1 | 2020 | 8 | 0.050 |
Why?
|
| Quinolinic Acid | 1 | 2020 | 10 | 0.050 |
Why?
|
| Extinction, Psychological | 2 | 2014 | 23 | 0.050 |
Why?
|
| Motivation | 1 | 2023 | 314 | 0.050 |
Why?
|
| Kynurenine | 1 | 2020 | 21 | 0.050 |
Why?
|
| Neuroimaging | 1 | 2023 | 340 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2015 | 580 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 29 | 0.040 |
Why?
|
| Administration, Intranasal | 1 | 2020 | 134 | 0.040 |
Why?
|
| Epigenomics | 1 | 2021 | 164 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2009 | 4734 | 0.040 |
Why?
|
| Wakefulness | 1 | 2020 | 98 | 0.040 |
Why?
|
| Patient Health Questionnaire | 1 | 2019 | 16 | 0.040 |
Why?
|
| Prognosis | 1 | 2008 | 4554 | 0.040 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2018 | 66 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 2019 | 182 | 0.040 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2018 | 122 | 0.040 |
Why?
|
| Multilevel Analysis | 1 | 2017 | 8 | 0.040 |
Why?
|
| Multifactorial Inheritance | 1 | 2018 | 139 | 0.040 |
Why?
|
| Drug Overdose | 1 | 2018 | 65 | 0.040 |
Why?
|
| Genomics | 1 | 2006 | 1490 | 0.040 |
Why?
|
| Prescription Drugs | 1 | 2018 | 53 | 0.040 |
Why?
|
| Heart Rate | 1 | 2020 | 588 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 3137 | 0.030 |
Why?
|
| Sleep | 1 | 2020 | 343 | 0.030 |
Why?
|
| Psychoacoustics | 1 | 2016 | 3 | 0.030 |
Why?
|
| Hypertrophy | 1 | 2017 | 101 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2010 | 775 | 0.030 |
Why?
|
| Acoustic Stimulation | 1 | 2016 | 85 | 0.030 |
Why?
|
| Aging | 1 | 2003 | 1184 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 6470 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 426 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 3427 | 0.030 |
Why?
|
| Macaca mulatta | 2 | 2010 | 493 | 0.030 |
Why?
|
| Opioid-Related Disorders | 1 | 2018 | 261 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2019 | 495 | 0.030 |
Why?
|
| Rest | 1 | 2015 | 58 | 0.030 |
Why?
|
| Diagnostic Techniques, Endocrine | 1 | 2014 | 3 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 1017 | 0.030 |
Why?
|
| Exercise | 1 | 2020 | 821 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 1514 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 403 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2014 | 235 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1333 | 0.030 |
Why?
|
| Fatigue | 1 | 2014 | 219 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 1660 | 0.020 |
Why?
|
| Oxygen | 1 | 2015 | 554 | 0.020 |
Why?
|
| Maternal Deprivation | 1 | 2010 | 13 | 0.020 |
Why?
|
| Hospitalization | 1 | 2019 | 1756 | 0.020 |
Why?
|
| Spectrum Analysis | 1 | 2010 | 62 | 0.020 |
Why?
|
| Remission Induction | 1 | 2011 | 301 | 0.020 |
Why?
|
| Animals, Newborn | 2 | 2005 | 1008 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 1804 | 0.020 |
Why?
|
| Object Attachment | 1 | 2010 | 49 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 719 | 0.020 |
Why?
|
| Receptors, Dopamine | 1 | 2009 | 40 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 2122 | 0.020 |
Why?
|
| Obesity | 1 | 2020 | 2251 | 0.020 |
Why?
|
| Nasopharyngitis | 1 | 2008 | 5 | 0.020 |
Why?
|
| Capsules | 1 | 2008 | 21 | 0.020 |
Why?
|
| Atrophy | 1 | 2009 | 236 | 0.020 |
Why?
|
| Pregnancy | 1 | 2021 | 7167 | 0.020 |
Why?
|
| Dizziness | 1 | 2008 | 27 | 0.020 |
Why?
|
| Environment | 1 | 2009 | 145 | 0.020 |
Why?
|
| Nausea | 1 | 2008 | 97 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2021 | 8184 | 0.020 |
Why?
|
| Headache | 1 | 2008 | 109 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 1695 | 0.020 |
Why?
|
| Dopamine | 1 | 2009 | 284 | 0.020 |
Why?
|
| Child Behavior | 1 | 2009 | 234 | 0.020 |
Why?
|
| Phosphocreatine | 1 | 2006 | 9 | 0.020 |
Why?
|
| Agonistic Behavior | 1 | 2006 | 8 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2011 | 1129 | 0.020 |
Why?
|
| Wechsler Scales | 1 | 2006 | 21 | 0.020 |
Why?
|
| Amygdala | 1 | 2006 | 80 | 0.020 |
Why?
|
| Protons | 1 | 2006 | 91 | 0.020 |
Why?
|
| Insulin | 1 | 2011 | 1207 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2004 | 107 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2015 | 6089 | 0.010 |
Why?
|
| Rats | 1 | 2010 | 3687 | 0.010 |
Why?
|
| Memory | 1 | 2006 | 363 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 582 | 0.010 |
Why?
|
| Norepinephrine | 1 | 2002 | 173 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 4355 | 0.010 |
Why?
|
| Mice | 1 | 2010 | 17728 | 0.010 |
Why?
|